Shopping News / Articles
pharmaphorum
pharmaphorum. com > news > 23andme-study-explains-variable-results-obesity-drugs

23and Me study explains variable results with obesity drugs

6+ hour, 9+ min ago  (546+ words) Some people taking GLP-1 agonist-based weight-loss drugs have spectacular results, while others do less well and are affected badly by side effects " and a new study has started to explain why that is so. An analysis carried out by the…...

pharmaphorum
pharmaphorum. com > sales-marketing > how-war-middle-east-disrupting-medical-supply-chains

How war in the Middle East is disrupting medical supply chains

7+ hour, 38+ min ago  (650+ words) The conflict in the Middle East is sending shockwaves through the global economy and disrupting global trade. The region plays a vital role in global trade and logistics. Around one fifth of the world's oil supplies'normally'move through the Strait of…...

pharmaphorum
pharmaphorum. com > news > eu-invests-eu30m-fight-antimicrobial-resistance

EU invests "30m to fight antimicrobial resistance

1+ day, 6+ hour ago  (376+ words) The EU has pledged "30 million ($35 million) in funding for medical countermeasures to antimicrobial resistance (AMR), earmarked for the discovery and development of new antibacterial medicines. The investment will be managed by Germany's development bank, Kf W, and will be used…...

pharmaphorum
pharmaphorum. com > oncology > preclinical-toxicology-clinical-safety-path-oncology-ind-submissions

From preclinical toxicology to clinical safety: The path for oncology IND submissions

1+ day, 54+ min ago  (233+ words) In oncology, the dose schedule, in addition to dose duration, drives nonclinical design. The enabling study should mirror the intended clinical cadence closely enough that exposure-toxicity relationships can be applied to the first trial. For instance, if the clinical plan…...

pharmaphorum
pharmaphorum. com > news > activist-investor-renews-its-criticism-novavax

Activist investor renews its criticism of Novavax

1+ day, 3+ hour ago  (597+ words) Hedge fund Shah Capital has fired another broadside at vaccine developer Novavax, saying it intends to vote against the re-election of the board and executive pay packages at its forthcoming annual meeting. The activist investor, which holds a 9% stake in…...

pharmaphorum
pharmaphorum. com > oncology > advancing-case-cell-and-gene-therapies

Advancing the case for cell and gene therapies

1+ day, 4+ hour ago  (674+ words) Cell and gene therapy (CGT) has had a tough few years, with questions over cost, scalability and manufacturing making investors think twice about plunging in. But the depth and breadth of innovation taking place in the sector is staggering. Last…...

pharmaphorum
pharmaphorum. com > news > us-judge-blocks-bid-curb-abortion-pill-access

US judge blocks bid to curb abortion pill access

1+ day, 7+ hour ago  (509+ words) A legal bid to introduce a temporary block on remote access to the abortion pill mifepristone in the US, while the Trump administration carries out a review of the drug, has been turned down by a federal judge. A complaint…...

pharmaphorum
pharmaphorum. com > news > kennedy-changes-vaccine-panel-charter-after-legal-setback

Kennedy changes vaccine panel charter after legal setback

2+ day, 3+ hour ago  (362+ words) HHS Secretary Robert F Kennedy Jr has followed a court ruling that his controversial appointments to the CDC's Advisory Committee on Immunization Practices (ACIP) were unlawful by changing the panel's charter. The revised membership rules " which broaden the areas of…...

pharmaphorum
pharmaphorum. com > news > ai-giant-anthropic-buys-coefficient-bio-400m

AI giant Anthropic buys Coefficient Bio for $400m

2+ day, 4+ hour ago  (441+ words) Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio, a specialist in applying AI to drug discovery that was set up last year, but until now has been operating under the radar. San…...

pharmaphorum
pharmaphorum. com > news > sanofis-bispecific-lunsekimig-has-mixed-readouts-phase-2

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

2+ day, 5+ hour ago  (491+ words) A bispecific antibody that Sanofi thinks could be a future star of its immunology and inflammation business has hit the mark in two midstage trials in respiratory indications, but fallen short in a third in atopic dermatitis. On the plus…...

Shopping

Please enter a search for detailed shopping results.